In additional data presented at the congress, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment.
Was hoping for more than stabilize weight and metabolic profile, sounds like it won’t be lowering these for everyone 
. Thanks for posting.
I think what happened is that the percentage of people who took placebo and the percentage who took karxt were the same. At least when it comes to weight gain.
It has already been confirmed that it does not alter metabolic parameters. With which I would tell you that weight gain would be a very rare side effect.
The investigators found similar treatment-emergent adverse event rates between the KarXT and placebo groups for extrapyramidal motor symptoms (0% vs 0%), akathisia (1% vs 1%), weight gain (0% vs 1%), and somnolence (5% vs 4%), as well as comparable adverse event-related discontinuation rates (7% vs 6%).
People lose weight in fact on karxt, if you gain weight on it, it’s a bit weird
110 people, only 29 completed the course?
I may of misread though.
Am I wrong or does that say, placebo has more somnolence than KarXT group?
Still sounds promising.
Placebo has more weight gain, less sommolence